Page last updated: 2024-12-06
kelfiprim
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
kelfiprim: combination of trimethoprim & sulfametopyrazine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 64934 |
| MeSH ID | M0087922 |
Synonyms (7)
| Synonym |
|---|
| sulfalene + trimethoprim |
| benzenesulfonamide, 4-amino-n-(3-methoxypyrazinyl)-, mixt. with 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine |
| kelfiprim |
| trimed |
| 50933-06-7 |
| DTXSID50198966 |
| 4-amino-n-(3-methoxypyrazin-2-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine |
Research Excerpts
Overview
Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). " | ( Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections: multicenter double-blind trial. Cantaluppi, A; Chiarini, C; Graziani, G; Limido, D; Locatelli, F; Marai, P; Piaia, F; Pincella, G; Ponticelli, C; Zucchelli, P, 1987) | 3.16 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Multiple samples were collected over 9 days and the following pharmacokinetic parameters were calculated: total area under the plasma level curve, slow disposition rate constant beta and the corresponding t1/2 beta, plasma clearance and the apparent volume of distribution." | ( Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency. Cantaluppi, A; Grasso, S; Graziani, G; Meinardi, G; Piaia, F; Ponticelli, C; Tamassia, V, 1984) | 0.5 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination co-trimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim)." | ( A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. Bagnato, A; Colombo, F; Colombo, ML; Dei, D; Donno, L; Ginesu, F; Ortu, AR; Peona, V, 1984) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 18 (94.74) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (42.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (5.26%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (52.63%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||